GLP-1 Inhibits Gastric Emptying of Water but Does Not Influence Plasma Vasopressin, Sodium, or Osmolality

References

• Holst JJ. Enteroglucagon. Annu Rev Physiol 1997;59:257–71.
   PubMed Web of Science ®Google Scholar
• Bell GI, Santerre RF, Mullenbach GT. Hamster preproglucagon contains the sequence of glucagon and two related peptides. Nature 1983;302:716–8.
   PubMed Web of Science ®Google Scholar
• Wettergren A, Maina P, Boesby S, Holst JJ. Glucagon-like peptide-1 7–36 amide and peptide YY have an additive inhibitory effect on gastric acid secretion. Scand J Gastroenterol 1997; 32:552–5.
   PubMed Web of Science ®Google Scholar
• Turton MD, O’Shea D, Gunn I, Beak SA, Edwards CMB, Meeran K, et al. A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 1996;379:69–72.
   PubMed Web of Science ®Google Scholar
• Flint A, Raben A, Astrup A, Holst JJ. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest 1998;101:515–20.
   PubMed Web of Science ®Google Scholar
• Näslund E, Gutniak M, Skogar S, Rössner S, Hellström PM. Glucagon-like peptide-1 (GLP-1) increases the period of postprandial satiety and slows gastric emptying in obese humans. Am J Clin Nutr 1998;68: 525–30.
   Google Scholar
• Näslund E, Barkeling B, King N, Gutniak M, Blundell JE, Holst JJ, et al. Energy intake and appetite are suppressed by glucagonlike peptide-1 (GLP-1) in obese men. Int J Obes 1999;23: 304–11.
   Google Scholar
• Wettergren A, Schjoldager B, Mortensen PE, Myhre J, Christiansen J, Holst JJ. Truncated GLP-1 (proglucagon 87–107-amide) inhibits gastric and pancreatic functions in man. Dig Dis Sci 1993;38:665–73.
   PubMed Web of Science ®Google Scholar
• Willms B, Werner J, Ørskov C, Holst JJ, Creutzfeldt W, Nauck MA. Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7–36) amide in type 2 (noninsulin-dependent) diabetic patients. J Clin Endocrinol Metab 1996;81: 327–32.
   Google Scholar
• Schirra J, Leicht P, Hildebrand P, Beglinger C, Arnold R, GOke B, et al. Mechanisms of the antidiabetic action of subcutaneous glucagon-like peptide-1 (7–36) amide in non-insulin dependent diabetes mellitus. J Endocrinol 1998;156:177–86.
   PubMed Web of Science ®Google Scholar
• Naslund E, Bogefors J, Skogar S, Grybäck P, Jacobsson H, Holst JJ, etal. GLP-1 slows solid gastric emptying and inhibits insulin, glucagon, and PYY release in humans. Am J Physiol 1999; 277:R910–6.
   Google Scholar
• Nauck MA, Niedereichholz U, Ettler R, Holst JJ, Ørskov C, Ritzel R, et al. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinopropic effects in healthy humans. Am J Physiol 1997;273:E981–8.
   Google Scholar
• Navarro M, Rodriquez de Fonseca F, Alvarez E, Chowen JA, Zueco JA, Eng J, et al. Colocalization of glucagon-like peptide-1 (GLP-1) receptors, glucose transporter GLUT-2, and glucokinase mRNAs in rat hypothalamic cells: evidence for a role of GLP-1 receptor agonists as an inhibitory signal for food and water intake. J Neurochem 1996;67:1982–91.
   PubMed Web of Science ®Google Scholar
• Tang-Christiansen M, Larsen PJ, Göke R, Fink-Jensen A, Jessop DS, Møller M, et al. Central administration of GLP-1-(7–36) amide inhibits food and water intake in rats. J Physiol 1996; 271:R848–56.
   Google Scholar
• Wang T, Edwards GL, Baile CA. Glucagon-like peptide-1 (7–36) amide administered into the third cerebroventricle inhibits water intake in rats. Proc Soc Exp Biol Med 1998;219: 85–91.
   Google Scholar
• Gutzwiller JP, Göke B, Drewe J, Hildebrand P, Ketterer S, Handschin D, et al. Glucagon-like peptide-1: a potent regulator of food intake in humans. Gut 1999;44:81–6.
   PubMed Web of Science ®Google Scholar
• Urbain JL, Siegel JA, Charkes ND, Maurer AH, Malmud LS, Fisher RS. The two-component stomach: effects of meal particle size on fundal and antral emptying. Eur J Nucl Med 1989;15: 254–9.
   PubMedGoogle Scholar
• Gutniak MK, Larsson H, Heibner SJ, Juneskans OT, Holst JJ, Ahrén B. Therapeutic levels of glucagon-like peptide-1 can be obtained in humans by a buccal tablet. Diabetes Care 1996;19: 843–8.
   Google Scholar
• Deacon CF, Johnsen AH, Holst JJ. Degradation of glucagon-like peptide-1 in vitro yields an N-terminally truncated peptide which is a major endogenous metabolite in vivo. J Clin Endocrinol Metab 1995;80: 952–7.
   Google Scholar
• Ørskov C, Rabenhøj L, Kofod H, Wettergren A, Holst JJ. Production and secretion of amidated and glycine-extended glucagon-like peptide-1 (GLP-1) in man. Diabetes 1994;43: 535–9.
   PubMed Web of Science ®Google Scholar
• Näslund E, Backman L, Granström L, Stockeld D. Seven year results of vertical banded gastroplasty for morbid obesity. Eur J Surg 1997;163:281–6.
   Google Scholar
• Collins PJ, Horowitz M, Cok DJ, Harding PE, Shearman DJ. Gastric emptying in normal subjects—a reproducible technique using a single scintillation camera and computer system. Gut 1983;24:1117–25.
   PubMed Web of Science ®Google Scholar
• Kelly KA. Gastric emptying of liquids and solids: roles of proximal and distal stomach. Am J Physiol 1980;239:G71–6.
   PubMed Web of Science ®Google Scholar
• Camilleri M, Malagelada JR, Brown ML, Becker G, Zinsmeister AR. Relation between antral motility and the gastric emptying of solids and liquids in humans. Am J Physiol 1985;249:G580–5.
   PubMed Web of Science ®Google Scholar
• Dunphy JL, Taylor RG, Fuller PJ. Tissue distribution of rat glucagon receptor and GLP-1 receptor gene expression. Mol Cell Endocrinol 1998;141: 179–86.
   Google Scholar
• Tolessa T, Gutniak M, Holst JJ, Efendic S, Hellström PM. Glucagon-like peptide-1 retards gastric emptying and small bowel transit in the rat. Dig Dis Sci 1998;43: 2284–90.
   Google Scholar
• Imeryuz N, Yegen BC, Bozkurt A, Coskun T, Villanueva- Penacarrillo ML, Ulusoy NB. Glucagon-like peptide-1 inhibits gastric emptying via vagal afferent-mediated central mechanisms. Am J Physiol 1997;273:G920–7.
   Google Scholar
• Wettergren A, Wøjdemann M, Holst JJ. Glucagon-like peptide-1 inhibits gastro-pancreatic function by inhibiting central parasympathetic outflow. Am J Physiol 1998;275:G984–92.
   PubMed Web of Science ®Google Scholar
• Giralt M, Vergara P. Glucagonlike peptide-1 (GLP-1) participation in ileal brake induced by intraluminal peptones in rat. Dig Dis Sci 1999;44:322–9.
   PubMed Web of Science ®Google Scholar
• Johnson AK, Gross PM. Sensory circumventricular organs and brain homeostatic pathways. FASEB J 1993;7:678–86.
   PubMed Web of Science ®Google Scholar
• Zueco JA, Esquifino AI, Chowen JA, Alvarez E, Castrillon PO, Blazquez E. Coexpression of glucagon-like peptide-1 (GLP-1) receptor, vasopressin, and oxytocin mRNAs in neurons of the rat hypothalamic supraoptic and paraventricular nuclei: effect of GLP-1 (7–36) amide on vasopressin and oxytocin release. J Neurochem 1999;72:10–6.
   PubMed Web of Science ®Google Scholar
• Herman C, Goke R, Richter G, Fehman HC, Arnold R, Goke B. Glucagon-like peptide-1 and glucose dependent insulin releasing polypeptide plasma levels in response to nutrients. Digestion 1995;56:917–62.
   Web of Science ®Google Scholar
• Todd JF, Edwards CMB, Ghatei MA, Mather HM, Bloom SR. Subcutaneous glucagon-like peptide-1 improves postprandial glycaemic control over a 3-week period in patients with early type 2 diabetes. Clin Sci 1998;95: 325–9.
   Google Scholar
• Ørskov C, Wettergren A, Holst JJ. Secretion of the incretin hormones glucagon-like peptide-1 (GLP-1) and gastric inhibitory peptide (GIP) correlates with insulin secretion throughout the day. Scand J Gastroenterol 1996;31: 665–70.
   Google Scholar
• Deacon CF, Nauck MA, Nielsen MT, Pridal L, Holst JJ. Both subcutaneously and intravenously administered glucagon-like peptide-1 are rapidly degraded from the amino terminus in type II diabetic patients and healthy subjects. Diabetes 1995;44: 1126–31.
   Google Scholar
• Larsen J, Jallad D, Damsbro P. One week continuous infusion of GLP-1 (7–37) improves glycemic control in NIDDM. Diabetes 1996;45 Suppl 2:233A.
   Google Scholar